Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (535)	3/4/2004 1:10:19 PM
From: Jibacoa	Respond to of 3722

GERN Had a pretty good run in 2003. Starting from its March 17 close at 1.73 it was able to keep its Up-Trend until its Sep.24 H at 16.07 (That was a 828.9% run in 6 months or 1856% annualized.<g>) The Sep.27-Oct.14 rally in 2003 was not that impressive (from the L on Sep.26 at 12.03 the H on Oct.14 at 16.80 (that was a 39.65% run in 3 weeks or 687.2% annualized <g>)and the volume on Oct.14 was only 8.799M compared with the 23.217M on Sep.24 GERN seems to have found support at the 8.50 level. It still hasn't broken its present downtrend.(It needs to close above 11.20 in order to test the more important resistance at 12.45 bigcharts.marketwatch.com GERN has been trying to develop a telomerase cancer vaccine and also to use its telomerase research to develop markers for possible cancer diagnosis and screening. Its research on human embryonic stem cells seems to have good potential including organ and tissue transplants and further research in human developmental biology. The acquisition of Roslin Bio-Med 5 yrs ago has also given the company an entry on research on nuclear transfer and the possibility of creation of cloned animals. On a close above 12.45 GERN could start a run to test its resistance above the 18.50 level <g> bigcharts.marketwatch.com Bernard